The Epidemiology and Attributable Outcomes of Candidemia in Adults and Children Hospitalized in the United States: A Propensity Analysis
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Candida species are the fourth most common cause of bloodstream infection and are the leading cause of invasive fungal infection among hospitalized patients in the United States. However, the frequency and outcomes attributable to the infection are uncertain. This retrospective study set out to estimate the incidence of candidemia in hospitalized adults and children in the United States and to determine attributable mortality, length of hospital stay, and hospital charges related to candidemia. METHODS: We used the Nationwide Inpatient Sample 2000 for adult patients and the Kids' Inpatient Database 2000 for pediatric patients. We matched candidemia-exposed and candidemia-unexposed patients by the propensity scores for the probability of candidemia exposure, which were derived from patient characteristics. Attributable outcomes were calculated as the differences in estimates of outcomes between propensity score-matched patients with and without candidemia. RESULTS: In the United States in 2000, candidemia was diagnosed in an estimated 1118 hospital admissions of pediatric patients and 8949 hospital admissions of adult patients, yielding a frequency of 43 cases per 100,000 pediatric admissions (95% confidence interval [CI], 35-52 cases per 100,000 pediatric admissions) and 30 cases per 100,000 adult admissions (95% CI, 26-34 cases per 100,000 adult admissions). In pediatric patients, candidemia was associated with a 10.0% increase in mortality (95% CI, 6.2%-13.8%), a mean 21.1-day increase in length of stay (95% CI, 14.4-27.8 days), and a mean increase in total per-patient hospital charges of 92,266 dollars (95% CI, 65,058 dollars-119,474 dollars). In adult patients, candidemia was associated with a 14.5% increase in mortality (95% CI, 12.1%-16.9%), a mean 10.1-day increase in length of stay (95% CI, 8.9-11.3 days), and a mean increase in hospital charges of 39,331 dollars (95% CI, 33,604 dollars-45,602 dollars). CONCLUSION: The impact of candidemia on excess mortality, increased length of stay, and the burden of cost of hospitalization underscores the need for improved means of prevention and treatment of candidemia in adults and children.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Carefully matched, retrospective cohort studies have been undertaken to estimate mortality attributable to candidemia and report rates ranging from 10% to 49%.[10][11][12][13][14][15]”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [12]
In the citing paper
“Estimates from numerous studies suggest the added hospital cost is as much as $40,000 per case.[10][11][12][16][17][18][19][20]”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [12]
In the citing paper
“Risk factors for invasive candidiasis include surgery (especially abdominal surgery), burns, long-term stay in an intensive care unit, and previous administration of broad-spectrum antibiotics and immunosuppressive agents [7–10].”
From Candida Infections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents (2013) · cites this paper as [8]
Citations
Cites
The epidemiology of sepsis in the United States from 1979 through 2000
Martin, G. S., Mannino, D. M., Eaton, S., & Moss, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022139 · Cited by 5,841
Infectious Diseases Society of America
Enders, J. F. (1969) · Journal of Infectious Diseases · doi:10.1093/infdis/119.3.317 · Cited by 3,286
Influenza-Associated Hospitalizations in the United States
Thompson, W. W. (2004) · JAMA · doi:10.1001/jama.292.11.1333 · Cited by 2,213
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440 · cited 1×
“comial bloodstream infection in the United States [1, 2]. Candidemia is frequently associated with the signs and symptoms of sepsis syndrome [3, 4 ]. A recent study of the epidemiology of sepsis revealed that the annual number of cases of sepsis caused by fungal organisms increased by 207% between 1979 and 2000 [5].”
BackgroundSelf-citationNosocomial Bloodstream Infections in United States Hospitals: A Three‐Year Analysis
Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/520192 · Cited by 1,387
Bronchiolitis-Associated Hospitalizations Among US Children, 1980-1996
Shay, D. K. (1999) · JAMA · doi:10.1001/jama.282.15.1440 · Cited by 1,385
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Goodman, J. L., Winston, D. J., Greenfield, R. A., Chandrasekar, P. H., Fox, B., Kaizer, H., Shadduck, R. K., Shea, T. C., Stiff, P., Friedman, D. J., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261301 · Cited by 1,174
Secular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990
Sague, C. M. B., Jarvis, W. R., & System, N. N. I. S. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1247 · Cited by 1,140
Attributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140
Research works printed but not linked: 1
- Rosamond, 2004, American Journal of Epidemiology, 160, 1137, 10.1093/aje/ · doi:10.1093/aje/ · Paper page
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Self-citationEpidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Self-citationHorn, D. L., Neofytos, D., Anaissie, E. J., Fishman, J. A., Steinbach, W. J., Olyaei, A. J., Marr, K. A., Pfaller, M. A., Chang, C., & Webster, K. M. (2009) · Clinical Infectious Diseases · doi:10.1086/599039 · Cited by 956
“Attributable mortality has been reported to range from 5% to 71%, and crude mortality rates have been reported to be as high as 81% [11–23].”
BackgroundEpidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Nosocomial fungal infections: epidemiology, diagnosis, and treatment
Perlroth, J., Choi, B., & Spellberg, B. (2007) · Medical Mycology · doi:10.1080/13693780701218689 · Cited by 738
Candida Infections of the Genitourinary Tract
Achkar, J. M., & Fries, B. C. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00076-09 · Cited by 736
Noble, S. M., French, S., Kohn, L. A., Chen, V., & Johnson, A. D. (2010) · Nature Genetics · doi:10.1038/ng.605 · Cited by 678
Hospital Epidemiology and Infection Control in Acute-Care Settings
Sydnor, E. R. M., & Perl, T. M. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00027-10 · Cited by 652
“The incidence of invasive candidiasis increased 15-fold between the 1970s and the 1990s (164, 257), and it has been estimated that the health care costs associated with invasive candidiasis in the United States total $2 billion to 4 billion per year (352, 366).”
BackgroundMicafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis
Pappas, P. G., Rotstein, C. M. F., Betts, R. F., Nucci, M., Talwar, D., De Waele, J. J., Vazquez, J. A., Dupont, B. F., Horn, D. L., Ostrosky-Zeichner, L., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/520980 · Cited by 638
Fluconazole resistance in Candida species: a current perspective
Berkow, E., & Lockhart, S. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s118892 · Cited by 542
Invasive Fungal Pathogens: Current Epidemiological Trends
Pfaller, M. A., Pappas, P. G., & Wingard, J. R. (2006) · Clinical Infectious Diseases · doi:10.1086/504490 · Cited by 448
An insight into the antifungal pipeline: selected new molecules and beyond
Ostrosky-Zeichner, L., Casadevall, A., Galgiani, J. N., Odds, F. C., & Rex, J. H. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3074 · Cited by 432
Spampinato, C., & Leonardi, D. (2013) · BioMed Research International · doi:10.1155/2013/204237 · Cited by 411
Pfaller, M., Neofytos, D., Diekema, D., Azie, N., Meier-Kriesche, H.-U., Quan, S.-P., & Horn, D. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.10.003 · Cited by 394
Candida auris: an Emerging Fungal Pathogen
Spivak, E. S., & Hanson, K. E. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01588-17 · Cited by 393
Kett, D. H., Azoulay, E., Echeverria, P. M., & Vincent, J.-L. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e318206c1ca · Cited by 389
Epidemiology of invasive candidiasis
Arendrup, M. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e84d2 · Cited by 376
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Bijie, H., Dzierzanowska, D., Klimko, N. N., Letscher-Bru, V., Lisalova, M., Muehlethaler, K., et al. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.01747-08 · Cited by 370
The Changing Epidemiology of Invasive Fungal Infections
Enoch, D. A., Yang, H., Aliyu, S. H., & Micallef, C. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-6515-1_2 · Cited by 370
Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin
Singh, S. D., Robbins, N., Zaas, A. K., Schell, W. A., Perfect, J. R., & Cowen, L. E. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000532 · Cited by 362
“[2,3].”
Cleveland, A. A., Farley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, S. R., Magill, S. S., Derado, G., Park, B. J., & Chiller, T. M. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis697 · Cited by 366
Falagas, M. E., Roussos, N., & Vardakas, K. Z. (2010) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2010.04.006 · Cited by 346
Tumbarello, M., Posteraro, B., Trecarichi, E. M., Fiori, B., Rossi, M., Porta, R., de Gaetano Donati, K., La Sorda, M., Spanu, T., Fadda, G., et al. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00131-07 · Cited by 343
Nosocomial Fungal Infections: Epidemiology, Infection Control, and Prevention
Alangaden, G. J. (2011) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2010.11.003 · Cited by 337
LaFayette, S. L., Collins, C., Zaas, A. K., Schell, W. A., Betancourt-Quiroz, M., Gunatilaka, A. A. L., Perfect, J. R., & Cowen, L. E. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001069 · Cited by 329
“The leading fungal pathogen of humans is Candida albicans, which ranks as the fourth most common cause of hospital acquired infectious disease and is associated with mortality rates approaching 50% [12,13,14].”
BackgroundEffect of silver nanoparticles on Candida albicans biofilms: an ultrastructural study
Lara, H. H., Romero-Urbina, D. G., Pierce, C., Lopez-Ribot, J. L., Arellano-Jiménez, M. J., & Jose-Yacaman, M. (2015) · Journal of Nanobiotechnology · doi:10.1186/s12951-015-0147-8 · Cited by 323
The French Mycosis Study Group, Lortholary, O., Renaudat, C., Sitbon, K., Madec, Y., Denoeud-Ndam, L., Wolff, M., Fontanet, A., Bretagne, S., & Dromer, F. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3408-3 · Cited by 312
Pande, K., Chen, C., & Noble, S. M. (2013) · Nature Genetics · doi:10.1038/ng.2710 · Cited by 306
Pachl, J., Svoboda, P., Jacobs, F., Vandewoude, K., van der Hoven, B., Spronk, P., Masterson, G., Malbrain, M., Aoun, M., Garbino, J., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/503428 · Cited by 307
Organ-Specific Innate Immune Responses in a Mouse Model of Invasive Candidiasis
Lionakis, M. S., Lim, J. K., Lee, C.-C. R., & Murphy, P. M. (2011) · Journal of Innate Immunity · doi:10.1159/000321157 · Cited by 302
Puig-Asensio, M., Padilla, B., Garnacho-Montero, J., Zaragoza, O., Aguado, J. M., Zaragoza, R., Montejo, M., Muñoz, P., Ruiz-Camps, I., Cuenca-Estrella, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12380 · Cited by 299
Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies
Falagas, M. E., Apostolou, K. E., & Pappas, V. D. (2006) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-006-0159-2 · Cited by 294
Hsp90 Governs Dispersion and Drug Resistance of Fungal Biofilms
Robbins, N., Uppuluri, P., Nett, J., Rajendran, R., Ramage, G., Lopez-Ribot, J. L., Andes, D., & Cowen, L. E. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002257 · Cited by 291
A multicenter study of septic shock due to candidemia: Outcomes and predictors of mortality.
Bassetti, M., Righi, E., Ansaldi, F., Merelli, M., Cecilia, T., De Pascale, G., Diaz-Martin, A., Luzzati, R., Rosin, C., Lagunes, L., et al. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3310-z · Cited by 284
Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.
Cowen, L. E., & Steinbach, W. J. (2008) · Eukaryotic Cell · doi:10.1128/ec.00041-08 · Cited by 285
McCarty, T. P., & Pappas, P. G. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.013 · Cited by 285
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Meis, J. F., Gould, I. M., Fu, W., Colombo, A. L., & Rodriguez-Noriega, E. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00409-07 · Cited by 284
Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series
Delsing, C. E., Gresnigt, M. S., Leentjens, J., Preijers, F., Frager, F. A., Kox, M., Monneret, G., Venet, F., Bleeker-Rovers, C. P., van de Veerdonk, F. L., et al. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-166 · Cited by 271
Sipsas, N. V., Lewis, R. E., Tarrand, J., Hachem, R., Rolston, K. V., Raad, I. I., & Kontoyiannis, D. P. (2009) · Cancer · doi:10.1002/cncr.24507 · Cited by 269
Candidemia and Invasive Candidiasis
McCarty, T. P., White, C. M., & Pappas, P. G. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.007 · Cited by 260
Epidemiology of Invasive Fungal Disease in Children
Pana, Z. D., Roilides, E., Warris, A., Groll, A. H., & Zaoutis, T. (2017) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/pix046 · Cited by 260
Self-citationCX3CR1-dependent renal macrophage survival promotes Candida control and host survival
Lionakis, M. S., Swamydas, M., Fischer, B. G., Plantinga, T. S., Johnson, M. D., Jaeger, M., Green, N. M., Masedunskas, A., Weigert, R., Mikelis, C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci71307 · Cited by 230
Bassetti, M., Merelli, M., Righi, E., Diaz-Martin, A., Rosello, E. M., Luzzati, R., Parra, A., Trecarichi, E. M., Sanguinetti, M., Posteraro, B., et al. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.01998-13 · Cited by 228
Bougnoux, M.-E., Kac, G., Aegerter, P., d’Enfert, C., Fagon, J.-Y., & CandiRea Study Group (2008) · Intensive Care Medicine · doi:10.1007/s00134-007-0865-y · Cited by 224
“Our results should help to optimize initial empiric treatments of Candida infections in ICU patients, which appears to be an important prognostic factor [6, 7, 35, 36].”
ResultAzie, N., Neofytos, D., Pfaller, M., Meier-Kriesche, H.-U., Quan, S.-P., & Horn, D. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.06.012 · Cited by 222
Empirical Fluconazole versus Placebo for Intensive Care Unit Patients: A Randomized Trial
Schuster, M. G., Edwards, J. E., Sobel, J. D., Darouiche, R. O., Karchmer, A. W., Hadley, S., Slotman, G., Panzer, H., Biswas, P., & Rex, J. H. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-2-200807150-00004 · Cited by 210
Candida albicans-Induced Epithelial Damage Mediates Translocation through Intestinal Barriers
Allert, S., Förster, T. M., Svensson, C.-M., Richardson, J. P., Pawlik, T., Hebecker, B., Rudolphi, S., Juraschitz, M., Schaller, M., Blagojevic, M., et al. (2018) · mBio · doi:10.1128/mbio.00915-18 · Cited by 208
Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata
Singh-Babak, S. D., Babak, T., Diezmann, S., Hill, J. A., Xie, J. L., Chen, Y.-L., Poutanen, S. M., Rennie, R. P., Heitman, J., & Cowen, L. E. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002718 · Cited by 205
“Candida species are the fourth most common cause of hospital acquired blood-stream infections and are the most prevalent cause of invasive fungal infection worldwide, with mortality rates approaching 50% [7,18].”
BackgroundAndes, D. R., Safdar, N., Baddley, J. W., Alexander, B., Brumble, L., Freifeld, A., Hadley, S., Herwaldt, L., Kauffman, C., Lyon, G. M., et al. (2016) · Transplant Infectious Disease · doi:10.1111/tid.12613 · Cited by 182
Antifungal therapy with an emphasis on biofilms
Pierce, C. G., Srinivasan, A., Uppuluri, P., Ramasubramanian, A. K., & López-Ribot, J. L. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.08.008 · Cited by 173
Burden of Candidemia in the United States, 2017
Tsay, S. V., Mu, Y., Williams, S., Epson, E., Nadle, J., Bamberg, W. M., Barter, D. M., Johnston, H. L., Farley, M. M., Harb, S., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa193 · Cited by 163
Wu, Y., Du, S., Johnson, J. L., Tung, H.-Y., Landers, C. T., Liu, Y., Seman, B. G., Wheeler, R. T., Costa-Mattioli, M., Kheradmand, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07991-4 · Cited by 143
Klingspor, L., Tortorano, A. M., Peman, J., Willinger, B., Hamal, P., Sendid, B., Velegraki, A., Kibbler, C., Meis, J. F., Sabino, R., et al. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2014.08.011 · Cited by 137
Secular trends in candidemia-related hospitalization in the United States, 2000–2005
Zilberberg, M. D., Shorr, A. F., & Kollef, M. H. (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/591033 · Cited by 137
Epidemiology of hospitalizations associated with invasive candidiasis, United States, 2002-20121
Strollo, S., Lionakis, M. S., Adjemian, J., Steiner, C. A., & Prevots, D. R. (2016) · Emerging Infectious Diseases · doi:10.3201/eid2301.161198 · Cited by 129
Zilberberg, M. D., Kollef, M. H., Arnold, H., Labelle, A., Micek, S. T., Kothari, S., & Shorr, A. F. (2010) · BMC Infectious Diseases · doi:10.1186/1471-2334-10-150 · Cited by 128
Lionakis, M. S., Fischer, B. G., Lim, J. K., Swamydas, M., Wan, W., Richard Lee, C.-C., Cohen, J. I., Scheinberg, P., Gao, J.-L., & Murphy, P. M. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002865 · Cited by 118
“bloodstream infection in the US and worldwide [1].”
BackgroundDiezmann, S., Michaut, M., Shapiro, R. S., Bader, G. D., & Cowen, L. E. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002562 · Cited by 112
“albicans is the leading fungal pathogen of humans worldwide with mortality rates approaching 50%, and is the fourth most common cause of hospital-acquired infections [16,21,22].”
BackgroundGamaletsou, M. N., Walsh, T. J., Zaoutis, T., Pagoni, M., Kotsopoulou, M., Voulgarelis, M., Panayiotidis, P., Vassilakopoulos, T., Angelopoulou, M. K., Marangos, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12312 · Cited by 112
“Although the incidence of candidaemia varies greatly among different hospitals, countries and geographical areas, similar incidences have been reported in European and US studies [1,3,12].”
BackgroundSelf-citationNobbs, A. H., Vickerman, M. M., & Jenkinson, H. F. (2010) · Eukaryotic Cell · doi:10.1128/ec.00103-10 · Cited by 112
Lipolytic Enzymes Involved in the Virulence of Human Pathogenic Fungi
Park, M., Do, E., & Jung, W. H. (2013) · Mycobiology · doi:10.5941/myco.2013.41.2.67 · Cited by 110
Beyda, N. D., Lewis, R. E., & Garey, K. W. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r020 · Cited by 109
“(3) intrinsic FKS mutations, which are naturally occurring mutations in C.”
BackgroundCandida albicans specializations for iron homeostasis: from commensalism to virulence
Noble, S. M. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.09.006 · Cited by 104
Candida albicans biofilm formation is associated with increased anti‐oxidative capacities
Seneviratne, C. J., Wang, Y., Jin, L., Abiko, Y., & Samaranayake, L. P. (2008) · PROTEOMICS · doi:10.1002/pmic.200701097 · Cited by 104
Current Epidemiology of Candida Infection
Lockhart, S. R. (2014) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2014.08.001 · Cited by 101
Genetic Drivers of Multidrug Resistance in Candida glabrata
Healey, K. R., Jimenez Ortigosa, C., Shor, E., & Perlin, D. S. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01995 · Cited by 93
The role of the cell wall in fungal pathogenesis
Arana, D. M., Prieto, D., Román, E., Nombela, C., Alonso‐Monge, R., & Pla, J. (2009) · Microbial Biotechnology · doi:10.1111/j.1751-7915.2008.00070.x · Cited by 92
Moran, C., Grussemeyer, C. A., Spalding, J. R., Benjamin, D. K., & Reed, S. D. (2010) · American Journal of Infection Control · doi:10.1016/j.ajic.2009.06.014 · Cited by 91
Time to blood culture positivity as a marker for catheter-related candidemia
Ben-Ami, R., Weinberger, M., Orni-Wasserlauff, R., Schwartz, D., Itzhaki, A., Lazarovitch, T., Bash, E., Aharoni, Y., Moroz, I., & Giladi, M. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00214-08 · Cited by 90
“The estimated attributable outcomes of candidemia include excess mortality of 14% to 49% (5, 19), prolongation of hospital stay by 10 days (19), and increased expenditure of around 40,000 dollars per case (19).”
BackgroundFungal sensing enhances neutrophil metabolic fitness by regulating antifungal Glut1 activity
Li, D.-D., Jawale, C. V., Zhou, C., Lin, L., Trevejo-Nunez, G. J., Rahman, S. A., Mullet, S. J., Das, J., Wendell, S. G., Delgoffe, G. M., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.02.017 · Cited by 76
Shah, D. N., Yau, R., Weston, J., Lasco, T. M., Salazar, M., Palmer, H. R., & Garey, K. W. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr244 · Cited by 75
Mazi, P. B., Olsen, M. A., Stwalley, D., Rauseo, A. M., Ayres, C., Powderly, W. G., & Spec, A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac004 · Cited by 68
Occurrence, presentation and treatment of candidemia
Mikulska, M., Del Bono, V., Ratto, S., & Viscoli, C. (2012) · Expert Review of Clinical Immunology · doi:10.1586/eci.12.52 · Cited by 71
Horn, D. L., Ostrosky-Zeichner, L., Morris, M. I., Ullmann, A. J., Wu, C., Buell, D. N., Kovanda, L. L., & Cornely, O. A. (2010) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-009-0843-0 · Cited by 69
Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options
Ashley, E. D., Drew, R., Johnson, M., Danna, R., Dabrowski, D., Walker, V., Prasad, M., Alexander, B., Papadopoulos, G., & Perfect, J. (2012) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2012.01124 · Cited by 62
Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting
Lepak, A., & Andes, D. (2011) · Critical Care Clinics · doi:10.1016/j.ccc.2010.11.001 · Cited by 62
Epidemiology of Candida blood stream infections: experience of a tertiary care centre in North India
Chander, J., Singla, N., Sidhu, S. K., & Gombar, S. (2013) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.2623 · Cited by 61
Pasqualotto, A. C., de Moraes, A. B., Zanini, R. R., & Severo, L. C. (2007) · Infection Control & Hospital Epidemiology · doi:10.1086/516658 · Cited by 60
Kasper, L., Seider, K., Gerwien, F., Allert, S., Brunke, S., Schwarzmüller, T., Ames, L., Zubiria-Barrera, C., Mansour, M. K., Becken, U., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096015 · Cited by 59
Khandelwal, N. K., Chauhan, N., Sarkar, P., Esquivel, B. D., Coccetti, P., Singh, A., Coste, A. T., Gupta, M., Sanglard, D., White, T. C., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.807032 · Cited by 59
Velasco, E., & Bigni, R. (2008) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-008-0546-y · Cited by 59
Potent anti‐microbial activity of traditional Chinese medicine herbs against Candida species
Seneviratne, C. J., Wong, R. W. K., & Samaranayake, L. P. (2008) · Mycoses · doi:10.1111/j.1439-0507.2007.01431.x · Cited by 51
Blood Gene Expression Signatures Predict Invasive Candidiasis
Zaas, A. K., Aziz, H., Lucas, J., Perfect, J. R., & Ginsburg, G. S. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000715 · Cited by 48
Simvastatin inhibits Candida albicans biofilm in vitro
Liu, G., Vellucci, V. F., Kyc, S., & Hostetter, M. K. (2009) · Pediatric Research · doi:10.1203/pdr.0b013e3181bd5bf8 · Cited by 43
Zilberberg, M. D., & Shorr, A. F. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.04.008 · Cited by 42
Lara, H. H., & Lopez-Ribot, J. L. (2020) · Pathogens · doi:10.3390/pathogens9100784 · Cited by 36
“The opportunistic pathogenic fungus Candida albicans is the fourth most prevalent pathogen that cause nosocomial bloodstream infections (BSI) in the United States, with high mortality rates [7].”
BackgroundLrg1 Regulates β (1,3)-Glucan Masking in Candida albicans through the Cek1 MAP Kinase Pathway
Chen, T., Wagner, A. S., Tams, R. N., Eyer, J. E., Kauffman, S. J., Gann, E. R., Fernandez, E. J., & Reynolds, T. B. (2019) · mBio · doi:10.1128/mbio.01767-19 · Cited by 33
Decreasing rates of invasive candidiasis in pediatric hospitals across the United States.
Fisher, B. T., Ross, R. K., Localio, A. R., Prasad, P. A., & Zaoutis, T. E. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit679 · Cited by 35
Self-citationEvolutionary Dynamics of Candida albicans during In Vitro Evolution
Huang, M., McClellan, M., Berman, J., & Kao, K. C. (2011) · Eukaryotic Cell · doi:10.1128/ec.05168-11 · Cited by 34
Impact of Gamma Irradiation on the Properties of Magnesium-Doped Hydroxyapatite in Chitosan Matrix
Predoi, D., Ciobanu, C. S., Iconaru, S. L., Predoi, S. A., Chifiriuc, M. C., Raaen, S., Badea, M. L., & Rokosz, K. (2022) · Materials · doi:10.3390/ma15155372 · Cited by 29
Endogenous Candida endophthalmitis: Who is really at risk?
Seidelman, J., Fleece, M., Bloom, A., Lydon, E., Yang, W., Arnold, C., Weber, D. J., & Okeke, N. L. (2021) · Journal of Infection · doi:10.1016/j.jinf.2020.12.032 · Cited by 26
Clinical features and risk factors for blood stream infections of Candida in neonates
LIU, M., HUANG, S., GUO, L., LI, H., WANG, F., ZHANG, Q., & SONG, G. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2626 · Cited by 23
Darouiche, R. O. (2009) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2009.02.013 · Cited by 23
Orasch, C., Mertz, D., Garbino, J., van Delden, C., Emonet, S., Schrenzel, J., Zimmerli, S., Damonti, L., Mühlethaler, K., Imhof, A., et al. (2018) · Journal of Infection · doi:10.1016/j.jinf.2017.12.018 · Cited by 19
Suzuki, H., Perencevich, E. N., Diekema, D. J., Livorsi, D. J., Nair, R., Kralovic, S. M., Roselle, G. A., & Goto, M. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab105 · Cited by 20
A Proteomic Landscape of Candida albicans in the Stepwise Evolution to Fluconazole Resistance
Song, N., Zhou, X., Li, D., Li, X., & Liu, W. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02105-21 · Cited by 17
Essential role of hepcidin in host resistance to disseminated candidiasis
(2025) · doi:10.1016/j.celrep.2025.115649 · Cited by 9
Metadata
- Authors
- Zaoutis, T. E., Argon, J., Chu, J., Berlin, J. A., Walsh, T. J., & Feudtner, C.
- Affiliations
- Children's Hospital of Philadelphia (US)
- University of Pennsylvania (US)
- National Cancer Institute (US)
- Leonard Davis Institute of Health Economics (US)
- Corresponding author
- Zaoutis, T. E.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-11-01
- Volume
- 41
- Issue
- 9
- Pages
- 1232-1239
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2146558016
- Cited by
- 784
- References
- 37
- Citations by year
- 2026: 9 · 2025: 17 · 2024: 24 · 2023: 15 · 2022: 22 · 2021: 38 · 2020: 37 · 2019: 43 · 2018: 36 · 2017: 39 · 2016: 39 · 2015: 46 · 2014: 56 · 2013: 59 · 2012: 53
- FWCI
- 18.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Agency for Healthcare Research and Quality (K08 HS00002, U18 HS10399)
- National Institute of Allergy and Infectious Diseases (1K23AI0629753-01)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- candidemia, invasive fungal infections, Candida species, bloodstream infection, incidence, attributable mortality, length of hospital stay, hospital charges, hospitalized children, hospitalized adults, hospitalized infants, propensity score matching, National Inpatient Sample, Kids' Inpatient Database, health care costs, mortality burden
- MeSH terms
- Aged, Candidiasis, Child, Child, Preschool, Costs and Cost Analysis, Female, Hospitalization, Humans, Infant, Male, Middle Aged, Retrospective Studies, United States, Cohort Studies, Incidence, Fungemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.